Photo of Peter Palese

Peter Palese

  • PROFESSOR Medicine, Infectious Diseases
Print ProfilePrint Profile


  • Ph.D., University of Vienna



  • 2012 -
    Election to the Institute of Medicine of the National Academy of Sciences

  • 2012 -
    Sanofi–Institut Pasteur Award

  • 2010 -
    European Virology Award (EVA)
    European Society for Virology

  • 2006 -
    Robert Koch Prize

  • 2006 -
    Elected Member
    The German Academy of Sciences Leopoldina

  • 2002 -
    Corresponding Member
    Austrian Academy of Sciences

  • 2000 -
    National Academy of Sciences


The Palese Laboratory is interested in fundamental questions concerning the genetic make-up and the biology of viruses. Our group uses molecular biological techniques to understand how viruses replicate and how they interact with cells to cause disease in their hosts. Emphasis is on the study of RNA viruses, including influenza, paramyxo and corona (SARS) viruses.

There are four major research directions in our laboratory at the present time. (1) By genetically changing influenza viruses via recombinant DNA techniques, we are studying viral genes and gene products. Using these reverse genetics techniques, we are trying to develop novel influenza virus vaccines and vaccine vectors. (2) We are identifying intracellular proteins that interact with viral proteins, and we are studying the biological function(s) of these cellular proteins in the context of viral infections.  (3) Another interest is the identification of novel targets for antivirals. (4) Finally, we are studying the pathogenicity of viruses in animal models including transmission of influenza viruses in guinea pigs.

The Palese Laboratory is interested in training students and postdoctoral fellows who will become independent investigators in "molecular" studies of infectious viral diseases.


Chou YY, Vafabakhsh R, Doğanay S, Gao Q, Ha T, Palese P. One influenza virus particle packages eight unique viral RNAs as shown by FISH analysis. Proceedings of the National Academy of Sciences of the United States of America 2012 Jun; 109.

Pica N, Chou YY, Bouvier NM, Palese P. Transmission of influenza B viruses in the guinea pig. Journal of virology 2012 Apr; 86.

Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future microbiology 2012 Mar; 7.

Wang TT, Parides MK, Palese P. Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science (New York, N.Y.) 2012 Mar; 335.

Seibert CW, Rahmat S, Krammer F, Palese P, Bouvier NM. Efficient transmission of pandemic H1N1 influenza viruses with high-level oseltamivir resistance. Journal of virology 2012 Feb;.

Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, García-Sastre A, Palese P. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proceedings of the National Academy of Sciences of the United States of America 2012; 109: 2573.

Palese P, Wang TT. H5N1 influenza viruses: Facts, not fear. Proceedings of the National Academy of Sciences of the United States of America 2012; 109: 2211.

Pica N, Chou YY, Bouvier NM, Palese P. Transmission of Influenza B viruses in the Guinea Pig. Journal of virology 2012 Feb;.

Palese P. Don't censor life-saving science. Nature 2012; 481: 115.

Varga ZT, Palese P. The influenza A virus protein PB1-F2: killing two birds with one stone?. Virulence 2011; 2: 542.

Palese P, Wang TT, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P. Why do influenza virus subtypes die out? A hypothesis. mBio 2011; 2.

Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML, Moran TM, Palese P. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 5777.

Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 2010; 1.

Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, Palese P. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS pathogens 2010; 6.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Palese during 2013 and/or 2014. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • Avimex; Boehringer Ingelheim Corporation; ContraFect Corporation; Farmak; Lohmann Animal Health; MedImmune, LLC; Novartis / Genentech Inc. Partnership

Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.

  • Merck & Co., Inc.; sanofi-aventis

Royalty Payments:

  • Avimex; MedImmune, LLC

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • ContraFect Corporation; Vivaldi Biosciences Inc.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


Annenberg Building Floor 16 Room 16-20
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-7318
Fax: 212-722-3634